{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:09:55Z","timestamp":1772168995003,"version":"3.50.1"},"update-to":[{"DOI":"10.12688\/f1000research.24086.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000}}],"reference-count":10,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns5:p>A 58-year-old man presented with recurrence of chronic myeloid leukemia (CML) after complete molecular remission in the setting of non-compliance with imatinib. He was restarted on imatinib and was also noted to have IgG kappa monoclonal gammopathy of undetermined significance (MGUS). The patient re-achieved molecular remission after resumption of imatinib, but his MGUS progressed to smoldering myeloma and he was eventually diagnosed with multiple myeloma (MM) and initiated on treatment for MM with thalidomide, bortezomib and dexamethasone. He has responded well to treatment of the myeloma and continues concurrent maintenance imatinib treatment for CML and is being evaluated for bone marrow transplant. The association of two concurrent hematological malignancies, CML and MM, is very rare and has been infrequently reported in literature. The pathophysiology of this has not yet been fully understood. This case report reviews the various theories to explain this and discusses the potential challenges of simultaneous treatment of MM and CML.<\/ns5:p>","DOI":"10.12688\/f1000research.24086.2","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T11:40:07Z","timestamp":1600861207000},"page":"488","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient"],"prefix":"10.12688","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9043-0420","authenticated-orcid":false,"given":"Neeraja","family":"Swaminathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorab","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Dourado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"342-350","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"\u201cChronic myeloid leukaemia\u201d","volume":"370","author":"R Hehlmann","year":"2007","journal-title":"Lancet."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"6295","DOI":"10.4081\/hr.2016.6295","article-title":"Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib.","volume":"8","author":"N Ali","year":"2016","journal-title":"Hematol Rep."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"738428","DOI":"10.1155\/2014\/738428","article-title":"Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder.","volume":"2014","author":"J Maerki","year":"2014","journal-title":"Case Rep Hematol."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"293-300","DOI":"10.3349\/ymj.1993.34.3.293","article-title":"Multiple myeloma and chronic myelogenous leukemia: a case report with literature review.","volume":"34","author":"P Klenn","year":"1993","journal-title":"Yonsei Med J."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"858-868","DOI":"10.1046\/j.1365-2141.2003.04706.x","article-title":"Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents.","volume":"123","author":"A Pandiella","year":"2003","journal-title":"Br J Haematol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"699-704","DOI":"10.1007\/s12185-010-0546-4","article-title":"Uncommon case of chronic myeloid leukemia with multiple myeloma.","volume":"91","author":"M Ide","year":"2010","journal-title":"Int J Hematol."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"1336-1339","DOI":"10.1016\/j.leukres.2010.01.012","article-title":"Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib.","volume":"34","author":"G Carulli","year":"2010","journal-title":"Leuk Res."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"62-65","DOI":"10.1002\/hon.2586","article-title":"Multiple myeloma: Every year a new standard?","volume":"37 Suppl 1","author":"S Rajkumar","year":"2019","journal-title":"Hematol Oncol."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1431-33","DOI":"10.4103\/0973-1482.192762","article-title":"Development of plasma cell leukemia in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate.","volume":"14","author":"S Maral","year":"2018","journal-title":"J Cancer Res Ther."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1896-1904","DOI":"10.1038\/sj.leu.2403949","article-title":"Zolendronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.","volume":"19","author":"C Chuah","year":"2005","journal-title":"Leukemia."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/9-488\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-488\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/9-488\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T04:55:09Z","timestamp":1601441709000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/9-488\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":10,"URL":"https:\/\/doi.org\/10.12688\/f1000research.24086.2","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.28094.r71881","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.28094.r71881","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/9-488\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.28094.r71881, Mahesh Swaminathan, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA, 30 Sep 2020, version 2, indexed","URL":"https:\/\/f1000research.com\/articles\/9-488\/v2#referee-response-71881","order":0,"name":"referee-response-71881","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.26569.r65599, Pritish K. Bhattacharyya, Department of Pathology, Hackensack University Medical Center, Hackensack, NJ, USA, 09 Jul 2020, version 1, 1 approved, 1 approved with reservations","URL":"https:\/\/f1000research.com\/articles\/9-488\/v1#referee-response-65599","order":1,"name":"referee-response-65599","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The author(s) declared that no grants were involved in supporting this work","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Data associated with the article are available under the terms of the Creative Commons Zero \"No rights reserved\" data waiver (CC0 1.0 Public domain dedication).","order":0,"name":"copyright-info","label":"Copyright"}]}}